OIPE
NOV 1 8 2004
PATENT & TRADEMARK OFFICE

RCE 1/11/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Johannes PLATZEK et al.

Examiner: Lauren Q. WELLS

Serial No.: 09/672,049

Group Art Unit: 1617

Filed: September 29, 2000

Title: GALENICAL FORMULATIONS

REPLY

Enter w/RCE JRH

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The following is in response to the Office action dated June 16, 2004.

REMARKS

As previously explained, there is no basis from the prior art to motivate a skilled worker to combine paramagnetic perfluoroalkyl and diamagnetic perfluoroalkyl compounds in galenical formulations.

Nevertheless, in order to expedite prosecution, evidence of unexpected and significant advantages for the claimed invention over prior art expectations is being presented.

The attached four examples in the declaration compare galenical formulations that consist of (I) a paramagnetic perfluoroalkyl compound and a diamagnetic perfluoroalkyl compound, on the one hand, and (II) solely the paramagnetic perfluoroalkyl compound, on the other. As can be seen, in all cases, the formulation (I) is unexpectedly, significantly advantageous to the corresponding formulation (II) for use as contrast medium in MRI. The addition of a diamagnetic perfluoroalkyl compound to a paramagnetic perfluoroalkyl compound has significant, beneficial effects on the properties of the combination as a contrast medium. These